article thumbnail

Pharma contract manufacturing market to grow to $130bn by 2026

European Pharmaceutical Review

billion by 2026. percent compound annual growth rate (CAGR) of the market include the increasing commercialisation of generics and emerging technologies and small biotechs with limited or no production capabilities driving development in the biopharmaceutical sector. percent between 2021 and 2026 (the forecast period).

article thumbnail

On the clock: a collaborative approach to advancing adoption of RMM

European Pharmaceutical Review

billion in 2026. 2 Rapid methods are also necessary for compounded sterile preparations and positron emission tomographic (PET) products. Currently, there are more than 2,000 active clinical trials for cell and gene therapies, 1 with the market expected to grow from $8.6 billion in 2022 to $21.33

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Aseptic packaging market to value $35bn by 2033

European Pharmaceutical Review

According to a report by Research Nester, the global aseptic packaging market is projected to reach a revenue of $35 billion by 2033 and is estimated to reach a compound annual growth rate (CAGR) of 10 percent between 2023 and 2033. According to the report, European production has grown by approximately 5.4 percent annually in recent years.

article thumbnail

Handling HPAPIs safely – what does it take?

European Pharmaceutical Review

” Highly potent APIs are pharmacologically and biologically active compounds at low doses. The compounds require special handling due to their cytotoxicity in the NCEs and investigational new drug applications (INDs). Managing highly potent cytotoxic compounds in early phases and at a late stage is a complex process.

article thumbnail

CD19 CAR-T agents to boost blood cancer market

European Pharmaceutical Review

Breyanzi will exhibit the largest compound annual growth rate (CAGR) at 30 percent, compared to Yescarta’s CAGR of 9 percent. Breyanzi is approved for DLBCL, and a label expansion is anticipated for expansions into marginal zone lymphoma (MZL) and mantle cell lymphoma (MCL) in 2026 and 2028, respectively. billion in 2031.

article thumbnail

SMi’s 22nd Annual Pain Therapeutics Conference

pharmaphorum

Novel Compounds and Treatments for Pain: Opioids and the Alternatives. Million by 2026, growing at a CAGR of 4.40 % from 2019 to 2026. Sponsored by: CHDR. Conference Chairman: Richard Malamut, Chief Medical Officer, Collegium Pharmaceutical, Inc. The global Postoperative Pain Therapeutics Market was valued at USD 11.26

article thumbnail

Ipsen beefs up in oncology, buying US biopharma Epizyme

pharmaphorum

per share if Tazverik hits $250 million in annual sales in four consecutive quarters before the end of 2026, and $0.70 if the drug is cleared for the second-line FL inflation before 1 January, 2028. Ipsen’s CVR offer includes $0.30 The post Ipsen beefs up in oncology, buying US biopharma Epizyme appeared first on.